NASDAQ:BIIBBiogen Stock Price, Forecast & News

Biogen's stock was trading at $294.25 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, BIIB shares have decreased by 9.9% and is now trading at $265.12. View which stocks have been most impacted by Coronavirus.

31 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biogen in the last year. There are currently 5 sell ratings, 17 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Biogen.

Biogen is scheduled to release its next quarterly earnings announcement on Tuesday, July 28th 2020. View our earnings forecast for Biogen.

Biogen Inc (NASDAQ:BIIB) issued its quarterly earnings results on Wednesday, April, 22nd. The biotechnology company reported $9.14 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $7.73 by $1.41. The biotechnology company had revenue of $3.53 billion for the quarter, compared to analyst estimates of $3.41 billion. Biogen had a net margin of 40.76% and a return on equity of 49.22%. The company's revenue was up 1.3% compared to the same quarter last year. During the same period last year, the company earned $6.98 EPS. View Biogen's earnings history.

Biogen declared that its Board of Directors has initiated a share repurchase plan on Monday, December 23rd 2019, which allows the company to buyback $5,000,000,000.00 in shares, according to EventVestor. This buyback authorization allows the company to buy shares of its stock through open market purchases. Stock buyback plans are typically an indication that the company's management believes its shares are undervalued.

31 brokers have issued 1-year price objectives for Biogen's stock. Their forecasts range from $228.00 to $410.00. On average, they anticipate Biogen's share price to reach $308.59 in the next twelve months. This suggests a possible upside of 16.4% from the stock's current price. View analysts' price targets for Biogen.

News articles about BIIB stock have been trending negative this week, InfoTrie reports. The research group ranks the sentiment of press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Biogen earned a media sentiment score of -2.2 on InfoTrie's scale. They also gave news coverage about the biotechnology company a news buzz of 5.0 out of 10, meaning that recent press coverage is somewhat likely to have an effect on the stock's share price in the near future. View the latest news about Biogen.

Some companies that are related to Biogen include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Immunomedics (IMMU), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Biogen investors own include Gilead Sciences (GILD), NVIDIA (NVDA), Netflix (NFLX), Alibaba Group (BABA), Tesla (TSLA), Amgen (AMGN), Walt Disney (DIS), Celgene (CELG), Micron Technology (MU) and Intel (INTC).

Biogen trades on the NASDAQ under the ticker symbol "BIIB."

Biogen's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Thomasville National Bank (0.01%). Company insiders that own Biogen stock include Alexander J Denner, Brian S Posner, Michael D Ehlers, Michel Vounatsos, Robert W Pangia and Stephen A Sherwin. View institutional ownership trends for Biogen.

BIIB stock was sold by a variety of institutional investors in the last quarter, including Thomasville National Bank. Company insiders that have sold Biogen company stock in the last year include Brian S Posner, and Stephen A Sherwin. View insider buying and selling activity for Biogen.

Shares of BIIB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of BIIB stock can currently be purchased for approximately $265.12.

Biogen has a market capitalization of $43.26 billion and generates $14.38 billion in revenue each year. The biotechnology company earns $5.89 billion in net income (profit) each year or $33.57 on an earnings per share basis. Biogen employs 7,400 workers across the globe.

The official website for Biogen is www.biogen.com.

Biogen's mailing address is 225 BINNEY STREET, CAMBRIDGE MA, 02142. The biotechnology company can be reached via phone at 617-679-2000 or via email at [email protected]